单药吉西他滨(择菲)及单药泰素帝治疗老年非小细胞肺癌的临床观察

Observation of gemcitabin and docetaxel in treating elderly patients with non-small cell lung cancer

目的:观察单药吉西他滨与单药泰素帝治疗老年人非小细胞肺癌(NSCLC)的疗效。方法:选60岁以上老年非小细胞肺癌患者50例,A组26例,予择菲针600mg/m2d1、8、15,28天1周期,治疗2-4周期;B组24例,予泰素帝针36mg/m2每周1次,共6次,8周为1周期,共2-4周期。结果:两组有效率PR+CR分别为30.7%和33.3%,中位生存期分别为7.15月和6.74月。不良反应择菲主要是血小板减少和皮疹,泰素帝主要是过敏反应和关节疼痛。结论:择菲和泰素帝单药治疗老年非小细胞肺癌有效且副作用少。

Objective：To investigate the clinical efficacy of elderly patients with NSCLC treated with gemcitabin or docetaxel. Methods-Fifty patients aged over 60 were devided into two groups,26 cases in group A were given gemcib in 600mg/m2 one day,the schedule was repeated every 28 days,24 cases in group B were given docetaxel 36mg/m2 one weeks one time × 6,the scheduce was repeated every 56 days. Results：All patients accepted 2 -4 cycles treatment. The clinical effieacy（ CR ＋ PR）were 30.7% and 33.3% respectively. Median TTP were 7.15 months and 6.5g months,side effects were：group A drug eruption and leucocytopenig,group B light allergic response and joiht pain. Conclusion： Two drugs are well tolerated and effective in the treatment of elderly patients with NSCLC.